The project is expected to get underway in March 2025. Zydus Lifesciences on Tuesday said it will undertake development of a combination vaccine against shigellosis and typhoid. The company ...

Zydus Family Trust has bought an apartment in Oberoi Realty’s luxury housing project in Worli, Mumbai, for Rs 200 crore, according to IndexTap.com. The size of the flat is 17,384 sq ft and the ...

A stamp duty of ₹7.04 crore was paid, and the sale was registered on March 27. MUMBAI: Zydus Family Trust has purchased a luxury apartment at the upscale Three Sixty West in Worli for ₹200 crore.

Zydus Lifesciences announced today it will develop the world’s first combination vaccine targeting both typhoid fever and shigellosis, with financial backing from the Bill & Melinda Gates ...

The proposed acquisition shall act as a platform to execute our global MedTech strategy and a natural extension for Zydus having a proven track record in life sciences and wellness segments ...

(Image Credits: Pixabay) Zydus on Wednesday said that a breakthrough in the prevention of Cytomegalovirus (CMV) infection for haematopoietic stem cell transplant (HSCT) and kidney transplant patients.

The recent approval enables Zydus Lifesciences to produce and sell Apalutamide Tablets, 60 mg (a generic equivalent of Erleada) in the United States. Apalutamide is an androgen receptor inhibitor ...

Zydus Lifesciences Limited on Tuesday announced that the company has entered into exclusive negotiations to acquire majority Amplitude Surgical. Purchase consideration amounts to €256.8mn for 85 ...

Pharma shares were under selling pressure on March 27, as investors turned cautious over the possible business impact due to reciprocal tariffs, after US President Trump announced tariffs on cars ...

Zydus Lifesciences has entered exclusive negotiations to acquire a controlling stake in France-based medtech firm Amplitude Surgical SA for €256.8 million, the drugmaker said on Tuesday, as it ...

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) to ...

Zydus, a leading, discovery-based, global lifesciences company, announces the launch of ANVIMO (Letermovir), a breakthrough in the prevention of Cytomegalovirus (CMV) infection for haematopoietic ...